临床与神经解剖因素与慢性丛集性头痛中脑腹侧被盖区脑深部电刺激疗效的相关性
这项前瞻性观察队列研究纳入43例难治性慢性丛集性头痛患者,接受中脑腹侧被盖区脑深部电刺激治疗并随访至少1年,29例(67.4%)发作频率改善≥50%。发作频率中位数从每月140次降至56次,无严重不良事件;未发现可靠的临床预测因素,无应答者在眶额皮层等区域神经密度增高。
要点
- 中脑腹侧被盖区脑深部电刺激使67.4%的难治性慢性丛集性头痛患者发作频率改善≥50%。
- 发作频率中位数从每月140次降至56次,发作严重程度从10/10降至8/10,持续时间从110分钟降至60分钟。
- 无严重不良事件,最常见副作用为电池部位不适或疼痛(7例)和一过性复视和/或视振荡(6例)。
核心结论
- 中脑腹侧被盖区脑深部电刺激未出现严重不良事件,尽管无安慰剂对照,在长期随访中约三分之二患者有效。
- 本研究未发现可靠的临床疗效预测因素。
- 无应答者在与疼痛处理和自主神经功能相关脑区神经密度增高,这两者在慢性丛集性头痛病理生理中均突出。
研究设计与样本
- 前瞻性观察队列研究,纳入单中心三级神经科学中心多学科团队按常规诊疗连续治疗的难治性慢性丛集性头痛患者。
- 共43例患者,平均年龄53岁(SD 11.9),其中男性29例,平均慢性丛集性头痛病程12年(SD 7.4),随访至少1年(平均随访5.6年)。
- 所有患者术前接受T1加权结构MRI,采用多变量logistic回归比较临床特征,基于体素的形态学分析(VBM)比较无应答者与应答者的神经解剖差异。
主要发现
- 发作频率中位数从每月140次降至56次(Z=-4.95,p<0.001),发作严重程度从10/10降至8/10(Z=-4.83,p<0.001),持续时间从110分钟降至60分钟(Z=-3.48,p<0.001)。
- 29例(67.4%)患者发作频率改善≥50%,被归类为应答者。
- 无严重不良事件;最常见副作用为电池部位不适或疼痛(7例)和一过性复视和/或视振荡(6例)。
- 应答者与无应答者在人口学特征、头痛特征或合并症方面无差异。
- VBM显示无应答者在眶额皮层、前扣带皮层、前岛叶和杏仁核等多个脑区神经密度增高,差异有统计学意义(p<0.001)。
局限性
- 原文指出该研究无安慰剂对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Deep brain stimulation (DBS) of the ventral tegmental area (VTA) is a surgical treatment option for selected patients with refractory chronic cluster headache (CCH). We aimed to identify clinical and structural neuroimaging factors associated with response to VTA DBS in CCH. METHODS: This prospective observational cohort study examines consecutive patients with refractory CCH treated with VTA DBS by a multidisciplinary team in a single tertiary neuroscience center as part of usual care. Headache diaries and validated questionnaires were completed at baseline and regular follow-up intervals. All patients underwent T1-weighted structural MRI before surgery. We compared clinical features using multivariable logistic regression and neuroanatomic differences using voxel-based morphometry (VBM) between responders and nonresponders. RESULTS: Over a 10-year period, 43 patients (mean age 53 years, SD 11.9), including 29 male patients, with a mean duration of CCH 12 years (SD 7.4), were treated and followed up for at least 1 year (mean follow-up duration 5.6 years). Overall, there was a statistically significant improvement in median attack frequency from 140 to 56 per month (Z = -4.95, p < 0.001), attack severity from 10/10 to 8/10 (Z = -4.83, p < 0.001), and duration from 110 to 60 minutes (Z = -3.48, p < 0.001). Twenty-nine (67.4%) patients experienced ≥50% improvement in attack frequency and were therefore classed as responders. There were no serious adverse events. The most common side effects were discomfort or pain around the battery site (7 patients) and transient diplopia and/or oscillopsia (6 patients). There were no differences in demographics, headache characteristics, or comorbidities between responders and nonresponders. VBM identified increased neural density in nonresponders in several brain regions, including the orbitofrontal cortex, anterior cingulate cortex, anterior insula, and amygdala, which were statistically significant (p < 0.001). DISCUSSION: VTA DBS showed no serious adverse events, and, although there was no placebo control, was effective in approximately two-thirds of patients at long-term follow-up. This study did not reveal any reliable clinical predictors of response. However, nonresponders had increased neural density in brain regions linked to processing of pain and autonomic function, both of which are prominent in the pathophysiology of CCH.
引用
- Cheema S, Ferreira F, Parras O, et al. Association of Clinical and Neuroanatomic Factors With Response to Ventral Tegmental Area DBS in Chronic Cluster Headache. Neurology. 2023. PMID: 37848331. doi:10.1212/WNL.0000000000207750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。